scholarly journals Rosmarinic acid reverses non‐small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway

2020 ◽  
Vol 34 (5) ◽  
pp. 1142-1153 ◽  
Author(s):  
Xiao‐Zhong Liao ◽  
Ying Gao ◽  
Ling‐Ling Sun ◽  
Jia‐Hui Liu ◽  
Han‐Rui Chen ◽  
...  
Tumor Biology ◽  
2016 ◽  
Vol 37 (7) ◽  
pp. 9615-9624 ◽  
Author(s):  
Kyoung Ah Kang ◽  
Mei Jing Piao ◽  
Susara Ruwan Kumara Madduma Hewage ◽  
Yea Seong Ryu ◽  
Min Chang Oh ◽  
...  

2020 ◽  
Vol 20 (4) ◽  
pp. 299-306
Author(s):  
Xiyang Peng ◽  
Yao Wen ◽  
Lagabaiyila Zha ◽  
Jian Zhuang ◽  
Li Lin ◽  
...  

Background: Previously, we first identified the human tripartite motifcontaining protein 45 (TRIM45) acts as a novel transcriptional repressor in mitogenactivated protein kinase (MAPK) signaling pathway. After that, the inhibitory role of TRIM45 in the development of tumor was gradually unveiled. However, the function of TRIM45 in the tumorigenesis of lung cancer has not been characterized. Methods and Results: In this study, we found that TRIM45 was up-regulated in earlystage human non-small-cell lung cancer (NSCLC) tissues. Overexpression of TRIM45 in lung cancer cells induces G1 arrest and promotes apoptosis, which accompanied by upregulated expression of RB, p16, p53, p27Kip1, and Caspase3 and down-regulated expression of CyclinE1 and CyclinE2. Further detection of the expression of the molecules in the MAPK signaling pathway revealed that overexpression of TRIM45 in lung cancer cells promotes phosphorylated p38 (p-p38) activation and inhibits phosphorylated ERK (p-ERK) activation. In accordance with this, p-p38 is increased while p-ERK is decreased in lung cancer tissues. Conclusion: These findings indicate that TRIM45 plays an inhibitory role in the tumorigenesis of lung cancer. High-level expression of TRIM45 in lung cancer tissue may promote cell apoptosis by activating p38 signal and inhibit proliferation by down-regulating p-ERK, which provides a new clue for understanding the tumorigenesis of lung cancer.


2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Jing Han ◽  
Yang Liu ◽  
Sen Yang ◽  
Xuan Wu ◽  
Hongle Li ◽  
...  

AbstractBRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer.


Sign in / Sign up

Export Citation Format

Share Document